Investing
688 Articles
Eli Lilly’s (NYSE:LLY | LLY Price Prediction) GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction,…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech:…
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is…
Eli Lilly (NYSE: LLY | LLY Price Prediction) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors…
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total…
Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” …
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO | NVO Price Prediction) has dropped 22% in the…
Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment…
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s…
24/7 Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue…
One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created…
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO)…
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of…
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on…
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution.…
Our top personal finance-related articles today. Your wallet will thank you later.